News & Updates
Filter by Specialty:
Gefitinib plus chemotherapy improves survival outcomes in mutated NSCLC brain metastases
Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.
Gefitinib plus chemotherapy improves survival outcomes in mutated NSCLC brain metastases
18 Feb 2023
Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
Several patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab report developing immune-related adverse events (irAEs), primarily affecting the skin, lungs, and gastrointestinal system, according to a study.
Immune-mediated reactions predict survival in nivolumab-treated NSCLC patients
18 Feb 2023
FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?
A combination of trifluridine/tipiracil (FTD/TPI) and bevacizumab provided significant survival benefit when used as third-line treatment for refractory metastatic colorectal cancer (CRC) than FTD/TPI alone, findings from the phase III SUNLIGHT study suggest.
FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?
16 Feb 2023
Risk model-based lung cancer screening more economical than USPSTF recommendation
Lung cancer screening based on a risk model is more cost-effective than the 2021 recommendation by the US Preventive Services Task Force (USPSTF), meriting further consideration for the former, reports a recent study.
